Infectious Disease

Research organizations around the world are deploying Simoa to combat COVID-19 and future pandemics with a full range of products, applications, and services including those listed below. In particular, Simoa’s extreme sensitivity and specificity is enabling researchers to measure cytokine levels and profiles in non-critical and critical COVID-19 patients as well as asymptomatic and symptomatic patients. 

We are actively seeking partners to work with us to develop viral loading and host immune response assays for both symptomatic and pre-symptomatic patients.  Let us know if you have ideas, assays and/or key reagents that could be combined with Simoa’s ultra-sensitivity.  

View our recent webinar to learn more about our efforts to prioritize support for COVID-19 research.

Announcing the winners of the Simoa Success Grant Program, aimed at supporting researchers at the intersection of laboratory and clinical research in Infectious Diseases and Immunology. Learn more now!

Simoa Cytokine Storm Profiling
Simoa Cytokine Storm Profiling

The Simoa technology is unique in its ability to simultaneously and precisely measure multiple cytokines down to baseline levels, enabling scientists to uncover a unique and comprehensive understanding of SARS-CoV-2 pathogenesis and host response.

Learn More

COVID-19 Webinar
COVID-19 Webinar

View our recent webinar to learn more about our efforts to prioritize support for COVID-19

Learn More

Studying the Key Role of Inflammation in Disease Progression and Severity
Studying the Key Role of Inflammation in Disease Progression and Severity

  • Up-regulation and suppression of Type I and Type II interferons (IFNα, IFNγ) as early predictors of disease severity
  • Pro-inflammatory cytokines (GM-CSF, IL-2, IL-6, IL-10, IL-12p70, TNFα) for early detection of imbalanced Th1 and Th2 response and risk for severe cytokine release
  • Biomarkers of chronic airway inflammatory disease (IL-4, IL-5, IL-13)
  • Airway remodeling (MMP-9) in virus-induced chronic pulmonary disease

Learn More
Characterizing Links between Viral Infection and Neurological Manifestations
Characterizing Links between Viral Infection and Neurological Manifestations

  • The role of circulating and CNS levels of chemokines (Eoxtaxin, IP-10, MCP-1) in neuroinflammation
  • Multiplex measurement of serum and plasma-based biomarkers of neurodegeneration (NF-l, GFAP, UCH-L1, tau)
  • Detection of biomarkers from dried blood spots enables use of remote sample collection protocols

Learn More
Measuring the Earliest Biomarkers of Myocardial Injury and Risk of Acute and Chronic Cardiac Disease
Measuring the Earliest Biomarkers of Myocardial Injury and Risk of Acute and Chronic Cardiac Disease

  • Ultra-sensitive measurement of changes in baseline levels of cardiac troponin I (cTnI) for determining risk of Acute Coronary Syndrome
  • Detection of natriuretic peptides (NT-proBNP) in monitoring chronic cardiac disease in COVID-19

Learn More
Developing New Ultra-Sensitive Assays for Viral Detection and Host Response
Developing New Ultra-Sensitive Assays for Viral Detection and Host Response

  • Quanterix’ unique homebrew ultrasensitive assay development capabilities provide the flexibility for researchers to develop singleplex and multiplex custom Simoa assays
  • Viral protein detection with PCR-level sensitivity with the speed and convenience of immunoassays
  • Serological assays to for characterizing host immune response, surveillance and vaccine development
  • Direct detection of nucleic acids using Simoa homebrew assay reagents to enable measurement of pathogen DNA and host miRNA biomarker levels without extraction or amplification

Learn More

Prioritized Access to CLIA-licensed Quanterix Accelerator Lab Services

Our CLIA-licensed Accelerator Services Laboratories harness our ultra -sensitive Simoa technology to support the research testing needs of our customers across a wide-range of applications and assays, including for neurology, oncology, infectious disease, and a wide range of critical biomarkers that can be used to track disease biology. We invite researchers whose in-house testing has been interrupted or who have emergent testing needs to contact Andy Keys (akeys@quanterix.com) to learn how our services can overcome interruptions or emergency testing needs.

Latest Publications

Samples require no pretreatment, no special handling and no molecular laboratory measures against carryover contamination associated with amplification methods.

Latest News

11.18
Learn more about groundbreaking Simoa technology! Simoa Success Seminars have gone virtual! We are excited to offer an extended lineup of webinar events, based on our popular seminar series.
11.11
Sampath Kumar NS, Chintagunta AD, Jeevan Kumar SP, Roy S and Kumar M. 3 Biotech 10, 527 (2020). DOI: https://doi.org/10.1007/s13205-020-02522-9 Abstract

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more